SCHEMBL4557892

SCHEMBL4557892

COc1cc2c(Nc3ccc(Cc4ccco4)cc3)ccnc2cc1OCCCN1CCOCC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 10/20 0.73
SRC P12931 8/20 0.57
KDR P35968 5/20 0.56
EGFR P00533 2/20 0.53
CIT O14578 1/20 0.53
GAK O14976 1/20 0.53
EPHB6 O15197 1/20 0.53
ABCC4 O15439 1/20 0.53
DAPK3 O43293 1/20 0.53
RIPK2 O43353 1/20 0.53
NR1I2 O75469 1/20 0.53
RPS6KA4 O75676 1/20 0.53
STK17B O94768 1/20 0.53
STK10 O94804 1/20 0.53
PRKD3 O94806 1/20 0.53
ABCB11 O95342 1/20 0.53
MAP4K4 O95819 1/20 0.53
CHEK2 O96017 1/20 0.53
ABL1 P00519 1/20 0.53
ERBB2 P04626 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4558340 0.88 MAP2K1 (0.71) MAP2K1SRCKDREGFRLCK
SCHEMBL4557789 0.87 MAP2K1 (0.73) MAP2K1SRCKDREGFRMET
SCHEMBL4456367 0.85 MAP2K1 (1.00) MAP2K1SRCEGFRERBB2
SCHEMBL27731209 0.83 KDR (0.62) SRCKDREGFRCITGAK
SCHEMBL4447904 0.83 MAP2K1 (0.72) MAP2K1SRCKDREGFRLCK
SCHEMBL18828353 0.83 SRC (0.57) MAP2K1SRCKDREGFRCIT
SCHEMBL12308286 0.82 EGFR (0.77) SRCKDREGFRCITGAK
SCHEMBL4445567 0.82 SRC (0.62) MAP2K1SRCKDREGFRLCK
SCHEMBL4447835 0.81 MAP2K1 (0.64) MAP2K1SRCKDRLCKMET
SCHEMBL6431410 0.78 EGFR (0.78) SRCKDREGFRCITGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009151910-A2 COMBINATION PRODUCT OF RECEPTOR TYROSINE KINASE INHIBITOR AND FATTY ACID SYNTHASE INHIBITOR FOR TREATING CANCER WYETH (US) 2009-12-17 WO disclosed